BioWorld MedTech

March 26, 2013

Deals roundup: Argon to acquire Angiotech interventional unit for $362M

In a move to perhaps eliminate a significant portion of its debt, Angiotech Pharmaceuticals (Vancouver, British Columbia) reported the sale of its interventional products business to Argon Medical Devices (Plano, Texas) for $362.5 million. Read More

Third Rock raises $516M in oversubscribed Fund III

Financings roundup: Bausch + Lomb files IPO registration statement

Washington roundup: FDA warning to Stryker offers no insight into Neptune recall

International report: Stereotaxis receives regulatory approval of Niobe tech in Japan

Agreements/contracts: Aerocrine, Medisoft agree to licensing settlement terms

Court report: BCBSM files motion to dismiss antitrust lawsuit filed against it

Grants roundup: Stanford pediatric cancer study receives funding

Med-Tech Notes

Product Briefs

People in the News

MDD's Cardio Extra

Today's news in brief

BioWorld

BioWorld briefs for May 22, 2026.

Acid alpha-glucosidase molecular structure isolated on black

‘Detargeted’ targeted gene therapy improves activity in Pompe

BioWorld

A new strategy aims to improve gene therapy for Pompe disease by optimizing both the genetic component that restores the function of a deficient lysosomal enzyme...

News in brief

BioWorld Asia

BioWorld Asia briefs for May 19, 2026

WHO declares Ebola outbreak a public health emergency of international concern

BioWorld

The threat posed by the Ebola outbreak in the Democratic Republic of Congo has intensified, with the confirmation that it is caused by the Bundibugyo species of...

Nxera Pharma prepares and tests new GPR17 antagonists

BioWorld Science

Nxera Pharma UK Ltd. has identified new uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists potentially useful for the treatment of...